MARKET

VTGN

VTGN

VistaGen
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.7968
+0.0679
+9.32%
After Hours: 0.7998 +0.003 +0.38% 18:39 01/24 EST
OPEN
0.7700
PREV CLOSE
0.7289
HIGH
0.7968
LOW
0.7200
VOLUME
171.17K
TURNOVER
--
52 WEEK HIGH
1.860
52 WEEK LOW
0.2943
MARKET CAP
34.44M
P/E (TTM)
-1.1354
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of VTGN and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 3 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

VTGN News

  • VistaGen +19% premarket on positive AV-101 results
  • Seeking Alpha - Article.12/19/2019 14:04
  • VistaGen and Baylor College of Medicine Announce Successful Results of First-Step Target Engagement Study with VistaGen's AV-101 Focused on Treating Suicidal Ideation in Veterans
  • PR Newswire.12/19/2019 13:30
  • CLNE, TRXC, TGE and ADMS among midday movers
  • Seeking Alpha - Article.12/17/2019 17:41
  • UL, CLVS among premarket losers
  • Seeking Alpha - Article.12/17/2019 14:12

More

Industry

Pharmaceuticals
-1.84%
Pharmaceuticals & Medical Research
-2.00%

Hot Stocks

Name
Price
%Change

About VTGN

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system (CNS). Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder (MDD) in patients with an inadequate response to standard antidepressants approved by the United States Food and Drug Administration (FDA). In addition to AV-101, the Company has developed a human pluripotent stem cell (hPSC) technology platform, which includes its in-vitro bioassay system, CardioSafe 3D, to predict potential heart toxicity of new chemical entities (NCEs) long before testing in animal and human studies. The Company is focused on regenerative medicine (RM) applications using blood, cartilage, heart and/or liver cells derived from hPSCs.
More

Webull offers Vistagen Therapeutics Inc (VTGN) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.